We envision a future where blood cancer patients benefit from safer, more effective therapies that improve their survival and quality of life.

We believe advanced and targeted therapies developed through predictive, reproducible, and patient-relevant preclinical technologies and processes can achieve that.

To make this happen, we develop human-, disease-, and patient-relevant bone marrow niche proxies as precisely defined context-of-use models to accurately reflect specific disease and patient biology, rather than one-fits-all models and approaches.

By bioengineering the biological potency and the drug-response-altering complexity of diseased bone marrow niches, we aim to improve predictions of toxicity and efficacy, including resistance and remission dynamics, before therapies reach patients.

Our goal is to accelerate the development of safe and efficacious treatments for bone-marrow-born hemato-oncological diseases by reducing late-stage drug attrition.

As pre-clinical drug development transitions beyond conventional models toward the integration of New Approach Methodologies (NAMs), Humaniche aims to become the trusted platform for translational validation of advanced therapies.